{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T10:03:40Z","timestamp":1790071420344,"version":"4.0.1"},"reference-count":28,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100018748","name":"Argenx","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018748","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J Peripheral Nervous Sys"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Aims<\/jats:title>\n                    <jats:p>In ADHERE, subcutaneous efgartigimod PH20 (1000\u2009mg once weekly) was effective and well tolerated in participants with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). ADHERE+ is an open\u2010label extension of ADHERE assessing long\u2010term safety and efficacy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Eligible participants from ADHERE run\u2010in period (prior CIDP treatments discontinued), stage A (open\u2010label efgartigimod), and stage B (stage A responders randomized to placebo or efgartigimod) could roll over to ADHERE+ and receive efgartigimod. The primary outcome was to assess long\u2010term safety and tolerability. Efficacy outcomes evaluated adjusted Inflammatory Neuropathy Cause and Treatment (aINCAT) score, Inflammatory Rasch\u2010built Overall Disability Scale (I\u2010RODS) score, and mean grip strength (GS) from ADHERE run\u2010in baseline through ADHERE+ week 36.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      At interim data cut\u2010off (February 16, 2024), 228\/229 eligible participants advanced to ADHERE+. Prolonged efgartigimod exposure did not increase the incidence (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009171\/228 [75.0%]) or severity of TEAEs (grade \u2265\u20093 TEAEs,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200941\/228 [18.0%]); regardless of immunoglobulin G level, there was a low incidence of infections. Stage A responders reported long\u2010term clinically meaningful improvements in mean aINCAT (decreased by 1.2 points), I\u2010RODS centile metric (increase of 8.8 points), and GS scores (increase of 17.5\u2009kPa) from run\u2010in baseline to ADHERE+ week 36, irrespective of stage B treatment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interpretation<\/jats:title>\n                    <jats:p>Interim results from ADHERE+ indicate long\u2010term efgartigimod PH20 treatment in participants with CIDP was well tolerated (maximum exposure\u2009=\u2009187.3 weeks; mean (SD) treatment duration\u2009=\u200958.0 [33.8] weeks). Clinically meaningful improvements in disability and strength were observed across assessments, regardless of stage B treatment or prior treatment status, with greater improvements seen over time.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/jns.70140","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T02:05:03Z","timestamp":1784253903000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Long\u2010Term Safety and Efficacy of Efgartigimod\n                    <scp>PH20<\/scp>\n                    in Chronic Inflammatory Demyelinating Polyradiculoneuropathy:\n                    <scp>ADHERE<\/scp>\n                    \/\n                    <scp>ADHERE<\/scp>\n                    + Trial Interim Analysis"],"prefix":"10.1111","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8753-2680","authenticated-orcid":false,"given":"Jeffrey A.","family":"Allen","sequence":"first","affiliation":[{"name":"University of Minnesota  Minneapolis Minnesota USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey","family":"Istas","sequence":"additional","affiliation":[{"name":"argenx  Ghent Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4716-8578","authenticated-orcid":false,"given":"Satoshi","family":"Kuwabara","sequence":"additional","affiliation":[{"name":"Chiba University  Chiba Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trevor","family":"Mole","sequence":"additional","affiliation":[{"name":"argenx  Ghent Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4289-8264","authenticated-orcid":false,"given":"Luis","family":"Querol","sequence":"additional","affiliation":[{"name":"Universitat Aut\u00f2noma de Barcelona  Barcelona Spain"},{"name":"Centro De Investigaci\u00f3n Biom\u00e9dica en Red en Enfermedades Raras (CIBERER)  Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Rinaldi","sequence":"additional","affiliation":[{"name":"University of Oxford  Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Stettner","sequence":"additional","affiliation":[{"name":"University Medicine Essen  Essen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Van Hoorick","sequence":"additional","affiliation":[{"name":"argenx  Ghent Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Lewis","sequence":"additional","affiliation":[{"name":"Cedars\u2010Sinai Medical Center  California Los Angeles USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,7,16]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.3390\/immuno2010009"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cger.2021.01.006"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1177\/1756285612457215"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/jns5.12053"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/ene.14959"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-021-10677-5"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2017.04.039"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2025-338140"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00159-9"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI97911"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00520"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1080\/08916934.2022.2104261"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1080\/10717544.2018.1551442"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2025.2497840"},{"key":"e_1_2_11_16_1","unstructured":"argenx \u201cargenx Announces VYVGART SC Prefilled Syringe for Self\u2010Injection in Chronic Inflammatory Demyelinating Polyneuropathy Authorized for Sale by Health Canada \u201d2025 https:\/\/www.newswire.ca\/news\u2010releases\/argenx\u2010announces\u2010vyvgart\u2010sc\u2010prefilled\u2010syringe\u2010for\u2010self\u2010injection\u2010in\u2010chronic\u2010inflammatory\u2010demyelinating\u2010polyneuropathy\u2010authorized\u2010for\u2010sale\u2010by\u2010health\u2010canada\u2010821841249.html."},{"key":"e_1_2_11_17_1","unstructured":"Food and Drug Administration \u201cVYVGART HYTRULO Prescribing Information \u201d2025 https:\/\/argenx.com\/content\/dam\/argenx\u2010corp\/products\/vyvgart\u2010hytrulo\u2010prescribing\u2010information.pdf."},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(24)00309-0"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2009.02930.x"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.28478"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1284444"},{"issue":"5","key":"e_1_2_11_22_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.neurot.2024.e00378","article-title":"Subcutaneous Efgartigimod PH20 in Generalized Myasthenia Gravis: A Phase 3 Randomized Noninferiority Study (ADAPT\u2010SC) and Interim Analyses of a Long\u2010Term Open\u2010Label Extension Study (ADAPT\u2010SC+)","volume":"21","author":"JF H.","year":"2024","journal-title":"Neurotherapeutics"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01460-5"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.20782"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2017-316427"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000590"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1186\/s41120-025-00108-4"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-021-00863-4"},{"issue":"1","key":"e_1_2_11_29_1","article-title":"Treatments for Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP): An Overview of Systematic Reviews","volume":"1","author":"Oaklander A. L.","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Journal of the Peripheral Nervous System"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jns.70140","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jns.70140","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jns.70140","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T09:15:03Z","timestamp":1790068503000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jns.70140"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,16]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1111\/jns.70140"],"URL":"https:\/\/doi.org\/10.1111\/jns.70140","archive":["Portico"],"relation":{},"ISSN":["1085-9489","1529-8027"],"issn-type":[{"value":"1085-9489","type":"print"},{"value":"1529-8027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,16]]},"assertion":[{"value":"2026-03-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70140"}}